1197815-overview Please confirm that you would like to log out of Medscape. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study Cancer Immunol Res .
10-15mg/m2/dose given intravenously on days 1 and 8 every 21 days for 2 to 6 cycles VI. 2002 Pegylated liposomal doxorubicin (doxorubicin HCl liposome injection; Doxil or Caelyx) is a liposomal formulation of doxorubicin, reducing uptake by the reticulo-endothelial system due to the attachment of polyethylene glycol polymers to a lipid anchor and stably retaining drug as a result of liposomal entrapment via an ammonium sulfate chemical gradient. Your list will be saved and can be edited at any time.The above information is provided for general Consult your pharmacist or local waste disposal company.Information last revised February 2020. These malignancies were diagnosed both during treatment with doxorubicin hydrochloride liposome injection and up to 6 years after the last dose. Diseases & Conditions
Follow applicable special handling and disposal procedures.Doxorubicin hydrochloride liposome injection: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) in single-dose vials. 2001 Can cause myocardial damage, including congestive heart failure, as the total cumulative dose of doxorubicin HCl approaches 550 mg/m²; In a clinical study of 250 patients with advanced cancer who were treated with liposomal doxorubicin, the risk of cardiotoxicity was 11% when the cumulative anthracycline dose was between 450-550 mg/m²
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. A phase III trial comparing standard-dose doxorubicin 50 mg/m 2 and ifosfamide 5 g/m 2, or an intensified arm combining doxorubicin 75 mg/m 2 and ifosfamide 5 g/m 2 with granulocyte-macrophage colony-stimulating factor support showed no difference in response rate or OS, though the PFS rate was higher in the dose-intensified arm. The risk of cardiomyopathy with doxorubicin hydrochloride is generally proportional to the cumulative exposure.
Indicated for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapyIndicated for ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapyIndicated in combination with bortezomib for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy30 mg/m² IV on day 4 following bortezomib 1.3 mg/m² on days 1, 4, 8 & 11 q3Weeks Hepatic impairment: Reduce dose if serum bilirubin ≥1.2 mg/dLMusculoskeletal and connective tissue disorders: Muscle spasmsRespiratory, thoracic and mediastinal disorders: Pulmonary embolism (in some cases fatal)Hematologic disorders: Secondary acute myelogenous leukemiaSkin and subcutaneous tissue disorders: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichenoid keratosisHistory of severe hypersensitivity to doxorubicin, including anaphylaxisSerious and sometimes life-threatening infusion-related reactions reported; ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation (see Black Box Warnings)Incidence of hand-foot syndrome in 1 trial was 51%, including 24% grade 3 or 4 toxicity (see Dosage Modifications)Secondary oral cancers, primarily squamous cell carcinoma, have been reportedBased on animal data, can cause fetal harm when administered to pregnant womenBased on findings in animals and its mechanism of action, therapy can cause fetal harm when administered to a pregnant woman; avoid use during the 1st trimesterVerify the pregnancy status of females of reproductive potential prior to initiating therapyNot known whether drug is present in human milk; because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from therapy, discontinue breastfeeding during treatmentA: Generally acceptable.
Growth of tumor cells was measured using the Sulphorhodamine‐B (SRB) assay.